Brind.

Natera has initiated the Phase II TEODOR trial.

1 report, 1 independent Updated Jul 30

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

TeodorNatera

Keep exploring

The entities involved

Natera
company in San Carlos, United States
- Natera and Fractyl Health, biotech companies, traded on the NASDAQ stock exchange on September 1, 2026.Mon 02:47
- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Sun 02:44

Coverage

Newest first; wire copies grouped

Jul 30Medical Device NetworkNatera initiates trial of Signatera test for breast cancer Natera has announced the initiation of the Phase II TEODOR trial of its Signatera test aimed at replacing chemotherapy with endocrine therap